This leads to a loss of tumor-reactive T cells systemically and subsequently to diminished efficacy of immunotherapy.22 These studies support the notion that liver metastatic tumors not only suppress intrahepatic antitumor immune response, but also inhibit systemic antitumor immunity, which leads to diminished response to PD-1/PD-L1 inhibition in this population. This evidence concerns the gene CD274 and neoplasm.